We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease
News

Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease

Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease
News

Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson’s disease. The finding could help explain an earlier outcome of the same study, in which the drug nilotinib was able to halt motor and nonmotor (cognition and quality of life) decline in the long term.

The researchers say their finding, detailed in a study published November 12, 2021, in Neurology Genetics, suggests that blood vessel walls called the blood-brain barrier, which normally act as a crucial filter to protect the brain against toxins as well as allow passage of nutrients to nourish it, doesn’t work correctly in some Parkinson’s patients: It prohibits toxins from leaving the brain and inhibits nutrients such as glucose from entering. Perhaps even more damaging, the dysfunctional barrier allows inflammatory cells and molecules from the body to enter and damage the brain.

The research, the first longitudinal study to use such advanced genomics, now provides investigators with a new target for therapeutic intervention in Parkinson’s disease, says the study’s senior author, Charbel Moussa, MBBS, PhD, director of the Medical Center’s Translational Neurotherapeutics Program.

The new discovery comes from the second part of a Phase II clinical trial that featured next-generation whole genome sequencing of the cerebrospinal fluid of 75 Parkinson’s patients, before and after treatment with a repurposed leukemia drug, nilotinib, or placebo.

This study lasted 27 months; the initial trial was double-blinded and patients were randomized to either placebo, or 150 milligrams or 300 milligrams nilotinib for 12 months. The patients had severe Parkinson’s disease; all were treated with optimal standard of care and many (30%) had also used the most sophisticated treatments possible, such as deep brain stimulation. The second part of the study employed an adaptive design, and all participants had a three-month drug washout period before re-randomization to either 150 milligrams or 300 milligrams for an additional 12 months. After 27 months, nilotinib was found to be safe, and patients who received nilotinib showed a dose-dependent increase of dopamine, the chemical lost as a result of neuronal destruction. 

“It appeared nilotinib halted motor and nonmotor decline in the patients taking the 300 milligrams higher dose,” says Moussa. The clinical outcomes of this study were published in Movement Disorders in March 2021.

The current part of the study just published examined the cerebrospinal fluid of patients via epigenomics, which is a systematic analysis of the global state of gene expression, in correlation with continuing clinical outcomes. The new analysis helps explain the clinical findings.

Nilotinib inactivated a protein (DDR1) that was destroying the ability of the blood brain barrier to function properly. When DDR1 was inhibited, normal transport of molecules in and out of the brain filter resumed, and inflammation declined to the point that dopamine, the neurotransmitter depleted by the disease process, was being produced again.

Moussa and his team have long been working on the effects that nilotinib (Tasigna) may have on neurodegeneration, including Alzheimer’s and Parkinson’s diseases. The drug was approved in 2007 for chronic myelogenous leukemia (CML), but Moussa reasoned that its mechanism of action may help the brain destroy toxins that develop in the brains of patients with neurodegenerative disorders.

“Not only does nilotinib flip on the brain’s garbage disposal system to eliminate bad toxic proteins, but it appears to also repair the blood brain barrier to allow this toxic waste to leave the brain and to allow nutrients in,” Moussa explains. “Parkinson’s disease is generally believed to involve mitochondrial or energy deficits that can be caused by environmental toxins or by toxic protein accumulation; it has never been identified as a vascular disease.”

“To our knowledge, this is the first study to show that the body’s blood brain barrier potentially offers a target for the treatment for Parkinson’s disease,” Moussa says. “Much work remains to be done, but just knowing that a patient’s brain vascular system is playing a significant role in the progression of the disease is a very promising discovery.”

In addition to Moussa, authors on the report include Alan J Fowler, MS; Jaeil Ahn, PhD; Michaeline Hebron, MS; Timothy Chiu; Reem Ayoub; Sanjana Mulki, MS; Habtom Ressom, PhD; Yasar Torres-Yaghi, MD; Barbara Wilmarth, NP; and Fernando L Pagan, MD.

Disclosures related to the study: 


Moussa is an inventor on several U.S. and international Georgetown University pending patent applications and issued patents to use nilotinib and other tyrosine kinase inhibitors as a treatment for neurodegenerative diseases. Moussa and Georgetown University previously received some income from the licensing of the intellectual property (IP) to a commercial partner. Currently, the IP is exclusively optioned to a startup company co-founded by Moussa and Pagan, who, along with Georgetown University, are equity holders. Moussa is a paid consultant to the company. Torres-Yaghi is an unpaid consultant to the company; Ahn is a paid consultant. Moussa received a grant from the National Institutes on Aging to study nilotinib in Dementia with Lewy bodies. The remaining authors report having no personal financial interests related to the study.

Reference:

Fowler AJ, Ahn J, Hebron M, et al. CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease. Neurology Genetics. 2021;7(6). doi:10.1212/NXG.0000000000000633

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement